NCT06455293

Psilocybin Therapy for Depression in Parkinson's Disease

Recruiting · Phase 2 · Joshua Woolley, MD, PhD · registry updated 2026-08-07

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Inclusion

Age 40 to 80
Comfortable speaking and writing in English
Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
Currently experiencing depressive symptoms
Able to attend all in-person visits at UCSF as well as virtual visits
Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating

Exclusion

Psychotic symptoms involving loss of insight
Significant cognitive impairment
Regular use of medications that may have problematic interactions with psilocybin
A health condition that makes this study unsafe or unfeasible, determined by study physicians

Open NCT06455293 on ClinicalTrials.gov All conditions